← SynDRA
ustekinumab
SynDRA canonical compound SYN0042216 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | TYMS |
|---|
| Mechanism of action | dihydrofolate reductase inhibitor |
|---|
| Indication | malaria |
|---|
| Disease area | infectious disease |
|---|
All known targets
- IL12A
- IL23A
- IL12B
- PDF
- TYMS
Mechanisms of action (all sources)
- IL12B INHIBITOR
- Interleukin-12 inhibitor
- IL12A INHIBITOR
- Interleukin-23 inhibitor
- IL23A INHIBITOR
- dihydrofolate reductase inhibitor
- PDF INHIBITOR
- IL12A ANTIBODY BINDING
- IL12B ANTIBODY BINDING
- IL23A ANTIBODY BINDING
Drug classes
- Dermatologic Agents
- Interleukin-12 Antagonists
- Interleukin-12 Antagonist
- Interleukin-23 Antagonists
- Interleukin-23 Antagonist
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- Pyzchiva
- Selarsdi
- Stelara
- stelara
- CNTO-1275
- WR99210
- WR 99210
- BRN 0629517
- WR-99,210
- CHEMBL129788
- BRL 6231
- Stelara (TN)
- Ustekinumab-aekn
- Ustekinumab-ttwe
- TT-20
- Stelera
- Uzpruvo
- Wezenla
- ustekinumab-auub
- ustekinumab-aekn
- ustekinumab-ttwe
Look up ustekinumab in the interactive SynDRA portal →